A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Summary

The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients with ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.

Timeline

Start

2015-07-09

Primary completion

2018-01-03

Completion

2018-01-03

Outcome

Outcome not reported

Stopped: “Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects”

Drugs

Indications